Exonuclease 1 (EXO1) is a 5’ to 3’ exonuclease, which is required for both DNA mismatch repair and DNA double-strand break (DSB) repair. Although there is no disease associated with EXO1 in OMIM, there was an early assertion of association with Lynch syndrome. Thus, it was curated for that disorder.
Summary of Genetic Evidence (Case Level): 0 point In 2001, Wu et al. (PMID: 11375940) first proposed the association of germline EXO1 variants in autosomal dominant Lynch syndrome by reporting 13 variants (splice site and missense) detected in 14 families with HNPCC or atypical HNPCC. This study also found that these variants did not occur in more than 200 control individuals. However, this study did not exclude germline MLH1, MSH2, and MSH6 mutations from the patients or use large control populations. Co-segregation of EXO1 variants with disease in these families was not tested. Additionally, the results from the first study were questioned by two subsequent publications (PMID: 12517792, 14756672), in which the authors confirmed that several variants observed in the patients with Lynch syndrome in the Wu et al. study were also observed in controls with similar frequencies, including the truncating variant previously proposed to be a disease-causing mutation. In addition, Alam et al. (PMID: 14623461) identified nine individuals carrying heterozygous germline deletions of 1q42.3 that include EXO1 gene. Theses individuals had multiple cutaneous and uterine leiomyomatosis, but they did not develop colorectal cancer or other Lynch syndrome spectrum cancers. No microsatellite instability (MSI) was detected from the EXO1-null skin leiomyomata tissues either.
Overall Summary: Considering the lack of substantial association in both genetic and experimental studies, there is convincing evidence refuting the gene-disease relationship between EXO1 and autosomal dominant Lynch syndrome. This gene-disease pair was originally evaluated as disputed on 6/8/2017 by Colon Cancer GCEP. This re-curation was approved by the ClinGen Hereditary Cancer GCEP on 5/26/2023 (SOP Version 9).
The GenCC data are available free of restriction under a CC0 1.0 Universal (CC0 1.0) Public Domain Dedication. The GenCC requests that you give attribution to GenCC and the contributing sources whenever possible and appropriate. The accepted Flagship manuscript is now available from Genetics in Medicine (https://www.gimjournal.org/article/S1098-3600(22)00746-8/fulltext).
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. The GenCC does not independently verify the submitted information. Though the information is obtained from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. The information is provided on an "as is" basis, collected through periodic submission and therefore may not represent the most up-to-date information from the submitters. If you have questions about the medical relevance of information contained on this website, please see a healthcare professional; if you have questions about specific gene-disease claims, please contact the relevant sources; and if you have questions about the representation of the data on this website, please contact gencc@thegencc.org.